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ABSTRACT 
The role of aromatase inhibitors in the management of breast cancer has been promising as it markedly suppresses the production of estrogen. The 
inhibitors are very effective in postmenopausal women and used as the first line therapy for hormone-sensitive breast cancer. The third generation 
aromatase inhibitors are advantageous having less adverse effects over other breast cancer drugs and they have also been recommended for use with 
tamoxifen. The aromatase inhibitors are of two different types; steroidal and nonsteroidal. Steroidal inhibitors are mechanism based inhibitors that 
mimic the natural substrate and are irreversible, unlike non-steroidal inhibitors which are reversible. The expression of aromatase occurs in a tissue 
specific manner with a set of distinctive transcription factors. In tumorous breast tissue, the enzyme is overexpressed with the help of four different 
promoters, I.3, I.4, I.7 and II and in turn, the growth stimulatory effects of estrogen is magnified to very high levels. Aromatase inhibition approach is 
considered as the gold standard and hence, in this review, we have discussed different types of aromatase inhibitors with their advantages. 
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INTRODUCTION 
Aromatase, being the key enzyme in the biosynthesis of estrogen, 
has acquired much attention as estrogen is the primary molecule 
that promotes the growth of normal and cancerous breast epithelial 
cells. Estrogen binds to estrogen receptors that get activated and 
bind to the promoters in the nucleus. Due to the activity of these 
estrogen receptors, cell division and blood vessel formation are 
enhanced. Moreover, binding of the estrogen receptors to the 
promoters also helps in inhibiting the cell death, thus promoting the 
tissue growth [1]. Aromatase is a cytochrome P450 enzyme 
catalyzing the critical rate limiting step (fig. 1), converts two 
different androgens; androstenedione and testosterone. It consists 
of a complex containing a cytochrome P450 protein and a 
flavoprotein NADPH cytochrome P450 reductase [2, 3]. The 
transcription of the enzyme is highly regulated and its gene coding 
for P450 protein has about 70kb which is the largest in its family. 
The polypeptide chain of the enzyme consists of 503 amino acids 
with a molecular weight of 55 kDa. It is placed in a separate CYP19 
family as its overall homology to other members of the P450 
superfamily is low [4, 5]. The region that encodes aromatase protein 
is about 30kb of the 3’ end which contains nine exons (II-X) [6]. 
Tissue specific expression of a number of promoters regulates the 
expression of aromatase through alternate splicing. Under 
physiological conditions, in disease free women, the aromatase 
expression is controlled at very low levels through promoter I.4 that 
is present 73kb upstream of the common coding region. There are 
other two promoters I.3 and II which are used very minimally in 
normal breast tissue [7]. However, the expression of the promoters 
I.3 and II is markedly increased to a very high level in breast tumor 
fibroblasts [7-10]. Additionally, yet another promoter I.7 is also 
overexpressed in breast tumor tissue and thus in breast cancer, a 
total of four different promoters contribute to the overexpression 
the enzyme and in turn, increasing the total aromatase mRNA levels 
when using promoter I.4 in normal breast tissue [11]. Hence, the 
inhibition of the enzyme is currently preferred over other modes of 
treatment for breast cancer and the drugs have been classified as 
“Aromatase Inhibitors (AIs)”. SERM (Selective Estrogen Receptor 
Modulator) and SERD (Selective Estrogen Receptor Down-
regulated) are other class of drugs that impact a variety of pathways 
regulated by activated estrogen receptors. Depending on the site of 
action, the SERMs will have either estrogen antagonist or agonist 
effects by modifying the expression of multiple genes whose 
transcription is regulated by estrogen receptors [12-16]. New 
approaches for treating breast cancer in postmenopausal women 
have also been proposed recently. An orphan nuclear receptor, 
DAX1, which is activated by the ligand activated androgen receptor, 
has been found to inhibit aromatase activity in breast cancer cell 
lines [17]. With the advent of newer genomic and transcriptomic 
techniques, personalized medicine is not an unreachable target. 
Breast cancer diagnostics has come a long way with advanced 
techniques such as real-time PCR, microarrays, Next Generation 
Sequencing leading to the identification of new biomarkers which 
would eventually help in the personalized management of treatment 
[18]. The role of miRNAs is being closely examined in the 
progression of breast cancer as they have been identified to be 
essential for the growth of HER2 positive breast cancer cells and 
further investigation would pave the way to develop strategies for 
prevention and treatment of breast cancer [19]. In this review, we 
have discussed the various types of aromatase inhibitors and its 
contribution in the treatment of breast cancer. 
Aromatase inhibitors 
Three generations of aromatase inhibitors have been in practice; 
each successive generation with higher specificity and less adverse 
effects. The list of aromatase inhibitors is tabulated in table 1. The 
third generation AIs are more specific with greater enzyme 
suppression [20-25]. These inhibitors can be pharmacologically 
divided into two different types as Type I and Type II; suicide 
inhibitors and competitive inhibitors respectively. The suicide 
inhibitors bind to the active site irreversibly and also leads to 
byproducts. They form covalent bonds in the active site or nearby 
the pocket inactivating the enzyme permanently and hence, they are 
of steroidal in nature. Type II, competitive inhibitors, on the other 
hand, prevent the product formation by binding reversibly to the 
active site. Once the inhibitor detaches, the active site becomes 
available to the substrate for binding. Unlike the suicide inhibitors, 
the competitive inhibitors could be steroidal or non-steroidal in 
nature [26]. As the aromatase inhibitors were more effective than 
the SERMs such as tamoxifen, the use of AIs increased drastically 
over the years. Moreover, the use of SERMs have a disadvantage of 
resistance in the women with ER+tumors that lack progesterone 
receptors. Overexpression of growth factors such as human 
epidermal growth factors also disrupted the effectiveness of the 
treatment [27, 28]. The most widely used SERM, tamoxifen was also 
found to increase late recurrence rates which might be due to its 
ability to act as estrogen agonists under differing conditions. Even 
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though this condition was attributed to prolonged use of tamoxifen, 
it urged the researchers to look for an alternate mode of treatment 
which resulted in the development of aromatase inhibitors that are 
effective regardless of progesterone receptor or growth factor 
receptors [27-31]. Metastasis is a major problem in any breast 
cancer as the tumorous cells spread to the distant sites such as 
lungs, liver, bone and brain. This stage is referred to as metastatic 
breast cancer, advanced breast cancer or secondary tumor. 
Aromatase inhibitors are more effective in the metastatic conditions 
when compared to tamoxifen by delaying the progression [32]. 
Aromatase inhibitors also have various adverse effects such as hot 
flashes, nausea, vomiting, fatigue, mood disturbances, musculoskeletal 
disorders, vaginal bleeding, vaginal discharge and vaginal dryness 
[33]. Moreover, recent studies have shown that the accumulation of 
p53 indicates recurrence in patients who were treated with aromatase 
inhibitors [34]. Amid such negative effects, aromatase inhibition is 
considered as Gold Standard for the treatment of early and advanced 
breast cancer as the advantages outweigh improving survival [35]. 
 
 
Fig. 1: Biosynthesis of estrogen 
 
Table 1: Aromatase inhibitors 
 1st generation 2nd generation 3rd generation 
Steroidal AIs Testololactone  Formestane Exemestane 
Nonsteroidal AIs Aminoglutethimide Fadrozole Anastrozole, Letrozole, Vorozole 
 
Steroidal aromatase inhibitors 
Testololactone was the first generation steroidal aromatase 
inhibitor, used widely more than aminoglutethimide, a non-steroidal 
inhibitor for treating advanced breast carcinoma. But, because of the 
misinterpretation of the mechanism of its action and the delay in 
determining its actual mechanism, i. e aromatase inhibition, the 
usage became obsolete soon [36]. Most of the clinical studies were 
conducted with testololactone were conducted prior to the time that 
its aromatase inhibition mechanism was unknown and this might 
have been a reason for its lower recognition [37]. It is a synthetic 
antineoplastic drug which is structurally similar to testosterone and 
its main action is the inhibition of conversion of androstenedione to 
estrone. Even though it is structurally similar to testosterone, it has 
never been found to be exerting androgenic activity. The drug can be 
easily produced from progesterone by microorganisms [38]. 
Testololactone was used in postmenopausal women as the main 
source of estrogen for them is estrone. The effect of the drug 
remains for a very long time even after the drug withdrawal. Due to 
its side effect and less potency as an inhibitor, industries came out 
with the second generation steroidal aromatase inhibitor, 
formestane (4-hydroxyandrostenedione) which is the first selective 
steroidal aromatase inhibitor and an analog to androstenedione. The 
performance of the drug, when compared with tamoxifen, had no 
significant difference except with time duration. Even then, since the 
drug was not active orally, the use was discontinued [39,40] which 
led to the development of third generation steroidal aromatase 
inhibitor, exemestane. Second and third generation inhibitors are 
more potent up to 1000 fold than the first generation drugs. As the 
half-life of the drugs is more, they are able to decrease the 
concentration of the circulating estrogen greatly [41]. Exemestane 
(6-methyleneandrosta-1,4-diene-3,17-dione) is structurally related 
to the natural substrate, androstenedione and hence, acting as a false 
substrate binding to the enzyme irreversibly. The drug has added the 
advantage of rapid absorption from the gut. It reaches high plasma 
concentration within about 1 hour in breast cancer patients; faster 
than healthy subjects where the absorption is about 3 h and mostly, 
the absorbed drug is bound to plasma proteins [42, 43]. The potent 
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activity of exemestane has been attributed to its different metabolites 
which eventually arises due to its complex metabolization. The four 
identified metabolites are tabulated in table 2. 
 
Table 2: Metabolites of exemestane 
S. No. Metabolites of exemestane 
1. 17β-hydroxy-6-methylenandrosta-1,4-dien-3-one (17-βHE) 
2. 6-(hydroxymethyl)androsta-1,4,6-triene-3,17-dione (6-HME) 
3. 6β-Spirooxiranandrosta-1,4-diene-3,17-dione (6-SPE) 
4. 1α,2α-epoxy-6-methylenandrost-4-ene-3,17-dione (1-EME) 
 
6-SPE was found to be more potent than the other metabolites 
resulting in an increase in the activity of MCF-7aro cells when 
compared to exemestane as the IC50 values were 0.25 μM and 0.90 
μM respectively [44]. Moreover, recent studies have demonstrated 
that the mechanism of action of the exemestane metabolites is 
different from that of exemestane. The metabolites, through the 
mitochondrial pathway, induced cell cycle arrest and apoptosis 
involving caspase-8 activation. They also induced the physiological 
cell destruction, autophagy promoting apoptosis and consequently, 
the aromatase inhibitor-resistant breast cancer cells were also 
sensitized due to enhanced apoptosis indicating that the efficacy of 
the exemestane may be dependent on the activity of its metabolites 
and not just exemestane [45]. The drug has also been found to be 
effective with everolimus, a mammalian target of rapamycin (mTOR) 
pathway inhibitor, which is promising as the aberrations in 
Phosphoinositide 3-kinase/protein kinase B/mammalian target of 
rapamycin (PI3K/AKT/mTOR) pathway are common in breast 
cancer. The increased resistance to endocrine therapies have been 
correlated with the mTOR pathway aberrations and hence, therapy 
with everolimus in combination with exemestane has been 
approved for use based on the Breast Cancer Trials of Oral 
Everolimus-2 (BOLERO-2) study [46].  
Nonsteroidal aromatase inhibitors 
Aminoglutethimide was primarily introduced as an anticonvulsant 
in 1960. It was observed that the drug had side effects including 
dizziness, drowsiness and ataxia. Adrenal insufficiency was also 
observed later which led to the withdrawal of the drug by FDA and 
on the other hand, led to series of studies determining its aromatase 
inhibition mechanism. Aminoglutethimide was the first nonsteroidal 
aromatase inhibitor and it was widely used in the treatment of 
metastatic breast cancer in postmenopausal women [47-50]. The 
drug has many advantages such as decreasing plasma estrone and 
estradiol concentrations up to 80%, and acceleration of metabolism 
of estrogen sulphate [51]. It was also observed through isotopic 
kinetic studies that aminoglutethimide is able to inhibit aromatase 
activity up to 90-95% [47]. The non-selectivity of the drug for 
aromatase led to very serious side effects as it was found to inhibit 
other cytochrome P450 mediated steroid hydroxylations and this 
mandated that the drug be combined with hydrocortisone [36, 50, 
51]. A fairly more potent second generation aromatase inhibitor, 
fadrozole replaced aminoglutethimide. Effective aromatase 
inhibition was observed even at lower concentrations [52]. The 
efficacy of the drug was compared with tamoxifen in trials and found 
that there was no significant difference in response rates and 
response duration [53, 54]. Considering the data generated out of 
various trials and experiments, it was demonstrated that fadrozole 
might be inferior to tamoxifen in efficacy. Even though the drug was 
approved for use in advanced breast cancer postmenopausal women 
in Japan, it was placed in third line therapy. Newer third generation 
drugs like anastrozole and letrozole were more potent and had more 
selectivity for the enzyme [41]. Anastrozole was the first 
nonsteroidal aromatase inhibitor to be approved in the US as it was 
able to inhibit the aromatase activity by 50% without having any 
effects on any molecules such as aldosterone, cortisol or thyroxine 
synthesis as that of previous versions. It was used at very low 
concentration of 0.1 mg/Kg orally for the management of breast 
cancer in postmenopausal women. The suppression of estradiol in 
patients was even up to levels approaching assay sensitivity. It was 
also found to be well tolerated than previous drugs and had less 
undesirable side effects such as weight gain, dyspnea, 
thromboembolic occurrences. The more attractive effect of 
anastrozole was that the survival advantage was higher up to 56% 
observed in a period of 2 y [55, 56]. Because of the superiority of the 
drug, it stays in the market to date even after the introduction of 
letrozole, yet another third generation nonsteroidal aromatase 
inhibitor. Letrozole has been approved for the management for 
metastatic breast cancer as it possesses considerable selectivity for 
aromatase [57]. The aromatase inhibition efficiency was detected 
using a highly sensitive DNA based estradiol assay and the results 
showed that the drug could decrease the plasma estradiol 
concentration up to 95% [58]. Letrozole administration over a wide 
dose range showed that it is highly selective for aromatase as there 
was no significant change in the levels of gonadotropins, ACTH, 
cortisol, aldosterone or TSH [59]. The toxicity was also tested with 
heavily treated postmenopausal breast cancer women and proved to 
be nontoxic with high clinical efficacy [60]. Vorozole is another 
highly potent and selective third generation nonsteroidal aromatase 
inhibitor. The efficacy of the drug is as similar as anastrozole and 
letrozole, but higher than aminoglutethimide [61]. Letrozole 
remains the preferred drug as it has also been found to be more 
advantageous when used with various small molecules such as 
dasatinib, palbociclib and buparlisib. Dasatinib, a Bcr-Abl tyrosine 
kinase inhibitor combined with letrozole improved the median 
progression free survival (PFS) from 11 mo to 22 mo in metastatic 
breast cancer (MBC) [62] and also, in combination with the cyclin 
dependent kinase inhibitor, palbociclib when tested with advanced 
estrogen receptor-positive and HER2-negative breast cancer 
women, significantly improved the PFS [63]. Apart from being used 
for treatment, aromatase inhibitors have been assessed for the 
prevention and reducing the recurrence in high risk 
postmenopausal women. In a study, it has been shown that 
anastrozole reduces the incidence of breast cancer in the women at 
high risk. The results are similar to the reduction in incidence due to 
exemestane in MAP.3 trial [64] and greater than the reduction in 
incidence due to tamoxifen [65]. The side effects due to the 
deprivation of estrogen were not attributed specifically to the 
treatment with anastrozole as they were also seen in the placebo 
group and most importantly, the risk of invasive estrogen receptor 
positive breast cancer was reduced to more than 50% [66]. A recent 
study reveals the advantage of using letrozole beyond 5 y in women 
with early breast cancer as it was beneficial in preventing 
recurrence. Moreover, the incidence of contralateral breast cancer 




Fig. 2: Anastrozole  Fig. 3: Letrozole 
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Fig. 5: Quercetin 
 
Natural aromatase inhibitors 
Various natural small molecules have been tested for aromatase 
inhibition activity. Most of the molecules are secondary metabolites 
and they have been assayed in both in vitro and in vivo. Among the 
molecules investigated, flavonoids are being investigated to a 
greater extent. Apart from flavonoids, terpenoids, peptides, lignans, 
xanthones, fatty acids, alkaloids, and other miscellaneous 
compounds having been evaluated [68]. Chrysin (5,7,4'-trihydroxy-
3',5'-dimethoxyflavone) was evaluated in microsomes, human 
preadipocyte cells, H295R adrenocortical carcinoma cells and in 
MCF-7 dual assay for its anti-aromatase activity [69-74]. Another 
common flavonoid tested in multiple studies is apigenin (5,7,4'-
trihydroxyflavone, 8). It has been found to be highly active in 
microsomes, Arom+HEK293 cells and granulosa-luteal cells [70-72, 
75, 76]. Apigenin is only moderately active in H295R adrenocortical 
carcinoma cells and not active in trout ovarian aromatase [74, 77]. 
Quercetin is natural dietary molecule that is present in many fruits 
and vegetables. It has been in use as a dietary supplement for a long 
time. The small molecule isolated from Epilobium capense and 
Morinda citrifolia L were found to have moderate inhibitory activity 
on aromatase [78]. Unsubstituted flavone, 7-Hydroxyflavone, 
Luteolin, 7,8-Dihydroxyflavone, 6-hydroxyflavone, 7-methoxy-
flavone, isolicoflavonol, broussoflavonol F, galangin, kaempferol, 
5,7,4'-trihydroxy-3'-methoxyflavone and rutin are other small 
molecules that have aromatase inhibition activity [68]. Apart from 
natural compounds, extracts have been shown to have anti-
aromatase activity. The extracts tested range from plants, edible 
fungi, spices, cycads to dietary substances and they were mostly 
investigated in microsomal assays. The extracts that showed activity 
on aromatase were from Dioon spinulosum, Encephalartos ferox, 
Riedelia Meisn. sp, Viscum album L, Cycas rumphii, Cycas revoluta, 
Alpinia purpurata etc. [79, 80].  
Advantages over tamoxifen 
The efficacy of the aromatase inhibitors over tamoxifen have been 
studied in many studies, particularly, the third generation aromatase 
inhibitors [81-84]. The nonsteroidal aromatase inhibitors, 
anastrozole and letrozole had better efficacy when compared with 
tamoxifen in two different studies where the 80% subjects were 
tamoxifen naive [83]. Even though anastrozole did not give 
statistically significant difference in Objective Response Rate (ORR), 
clinical benefit and time to progression (TTP), letrozole 
demonstrated superiority in all of these parameters [84]. In a 
randomized phase trial conducted by European Organization for 
Research and Treatment of Cancer (EORTC), the steroidal aromatase 
inhibitor, exemestane was compared with tamoxifen. The results 
were promising as: Exemestane and tamoxifen produced an ORR of 
40.9% and 13.6%; the clinical benefit of 55.7% and 42.4% 
respectively. Large trials were also conducted to prove the 
superiority of the third generation aromatase inhibitors over 
tamoxifen. Unlike other studies, the trial was involving multinational 
investigators and the results were confirming that the third 
generation aromatase inhibitors are superior in clinical efficacy with 
improved responses ranging from 2 to 13%. All the results were 
statistically significant except a trial in which the receptor status 
was unknown [85-87]. Toxicity was also compared between the use 
of tamoxifen and aromatase inhibitors in which the symptoms were 
comparable to some extents. Nausea, hot flashes and 
gastrointestinal distress were seen in both the treatments. Effects 
like deep venous thromboses and pulmonary emboli were 
significantly higher in tamoxifen than aromatase inhibitors. 
However, aromatase inhibitors associated side effects were also 
observed such as osteoporosis, osteopenia, arthralgias and myalgia 
[88,89]. Aromatase inhibitors have also been investigated in 
combination therapeutic approaches with tamoxifen. In ATAC 
(Anastrozole and Tamoxifen Alone and in Combination) trial, the 
effects like TTP, TTF and overall survival rates were compared [90]. 
After a 5 y follow up, in both the trials the aromatase inhibitors had 
superiority of about 3%. But the overall survival did not have much 
difference. Moreover, tamoxifen increased endometrial cancer and 
venothrombotic incidence whereas the aromatase inhibitors were 
associated with bone loss and urogenital atrophy symptoms [91-93]. 
A recent study, a meta-analysis that was conducted on 36889 
postmenopausal women with ER-positive invasive breast cancers to 
determine if the continuous or sequential regime of aromatase 
inhibitors is more effective than sequential tamoxifen monotherapy 
for preventing recurrence. The outcome of the analysis clearly 
revealed that the reduction in recurrence (827/4,970 vs 964/4,915, 
p<0.0001) was seen more with aromatase inhibitors than tamoxifen 
[94]. In a similar study, determination of recurrence rates showed 
that there is 30% reduction when compared with tamoxifen and 
moreover, 10-year breast cancer mortality rates were reduced by 
15% [95] indicating that the use of aromatase inhibitors in 
postmenopausal women is advantageous over tamoxifen having a 
better outcome and less toxicity. 
CONCLUSION 
Third generation inhibitors have gained an advantage over other 
endocrine therapies for the treatment of postmenopausal women in 
both early and metastatic breast cancers. They are effective not only 
alone but with other SERMs like tamoxifen. Additionally, they have 
also been helpful in adjuvant and neoadjuvant treatments [33,96-
98]. Prevention is another regime for any disease in which 
aromatase inhibitors could also be effective. On the other hand, 
estrogen is a necessary endocrine molecule which is also involved in 
biological processes other than endocrine function such as the brain, 
bone metabolism, energy expenditure, cardiovascular physiology, 
testis and prostate physiology and regulation of gonadotropin 
secretion. Hence, developing more advanced therapeutic approaches 
that can act on intratumoral production of estrogen, targeting only 
the cancerous cells would be the near future. 
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